Immunovant Financial Statements From 2010 to 2025
| IMVT Stock | USD 20.08 0.30 1.52% |
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as , as well as many indicators such as . Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
Immunovant |
Immunovant Company Current Valuation Analysis
Immunovant's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immunovant Current Valuation | 2.99 B |
Most of Immunovant's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunovant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immunovant has a Current Valuation of 2.99 B. This is 79.22% lower than that of the Biotechnology sector and 35.74% lower than that of the Health Care industry. The current valuation for all United States stocks is 82.04% higher than that of the company.
Immunovant Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunovant's current stock value. Our valuation model uses many indicators to compare Immunovant value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunovant competition to find correlations between indicators driving Immunovant's intrinsic value. More Info.Immunovant is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Immunovant by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Immunovant Financial Statements
Immunovant shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.